Blog Archives

Investor Relations Q&A Updates for PTIE, ONCY, RIGL, INSV, SNTI

9/30/2013

A new set of Investor Relations (IR) questions and responses from biotechs provided by Mike O'Neill has been posted, covering financials and upcoming catalysts for each biotech stock. These posts provide a great starting point for your due diligence research on each of these stocks. Answers are either provided directly by company executives or are summarized based on Mike's research.

This round of responses features PTIE Pain Therapeutics, ONCY Oncolytics Biotech, RIGL Rigel Pharma, INSV InSite Vision, and SNTI Senesco Technologies.

Check out the complete index of all IR Questions and Answers if you missed any of the previous editions - now covering dozens of biotech and pharmaceutical companies!

0 Comments

Weekend Biotech Reading List

9/28/2013

0 Comments

Department of Health and Human Services (HHS; includes FDA) Government Shutdown Contigency Plans
Big picture? 45% of FDA's nearly 15,000 employees would be furloughed

Open-Government Laws Fuel Hedge-Fund Profits
Hedge Funds Are Using FOIA Requests to Obtain Nonpublic Information From Federal Agencies
Brody Mullins and Christopher Weaver (Wall Street Journal)

Why Drug Companies Can't Tell The FDA About Every Research Project
John LaMattina (Forbes)
Duh...

What’s Behind The Booming Biotech IPO Market
Bruce Booth (LifeSci VC)

Pre-revenue biotech company valuations: flip a coin, throw a dart, do a DCF.
David Sable (and other secrets of the buy side)

0 Comments

"Fall is Here" Biotech Reading List

9/23/2013

0 Comments

The story of Elan, stranger than fiction
John Hearne (Irish Examiner)
Nice long-read on the peaks and valleys that made up the history of Elan $ELN.

My Favorite Biotech Due Diligence Question. A September ritual.
David Sable (and other secrets of the buy side)
First blog post in David's latest endeavor. Every subsequent post has been great, this is a must-have addition to your reading list.

Ten Tips for Raising Startup Capital in Biotech
Bruce Booth (LifeSciVC)
A remarkably useful list of topics for biotech investors to benchmark their publicly traded stocks against too!

Should Pharma Companies Give Up Discovery Research?
John LaMattina (Forbes)

Don’t Be Naïve: 7 Things to Know Before Taking a Biotech Startup Job
Luke Timmerman (Xconomy)

Agios CEO David Schenkein Makes the Case for Early-stage IPOs

0 Comments

Bonus Mid-week Biotech Reading List

9/9/2013

0 Comments

5 Things Biotechs Should Do to Take Advantage of The Boom
Dennis Purcell (Xconomy)

A little better than placebo is still better than nothing
Adrian Dobs (Nature Medicine)

Clinical trial transparency – The road ahead
Frank David (Pharmagellan)
Pharma Blasts EMA Draft Policy on Disclosing Clinical Trial Data
Ed Silverman (Pharmalot)

Which VCs Are Poised to Profit From the Biotech IPO Boom?
Luke Timmerman (Xconomy)

Earnings calls need a shake-up. But how?
Nicole Foderaro (Brew Life)

16 Essential Biotech Twitter Follows
Adam Feuerstein (The Street)
Honored to be included on the list - and yes, I follow and second the endorsement of the entire list! You can find other recognition for BiotechDueDiligence here.

0 Comments

Investor Relations Q&A Updates for VICL, BTX, IGXT, PSDV, ENZ

9/9/2013

0 Comments

A new set of Investor Relations (IR) questions and responses from biotechs provided by Mike O'Neill has been posted, covering financials and upcoming catalysts for each biotech stock. These posts provide a great starting point for your due diligence research on each of these stocks. Answers are either provided directly by company executives or are summarized based on Mike's research.

This round of responses features Vical Incorporated VICL, Enzo Biochem ENZ, IntelGenx IGXT, BioTime BTX, and pSivida Corp PSDV.

Check out the complete index of all IR Questions and Answers if you missed any of the previous editions - now covering dozens of biotech and pharmaceutical companies!

0 Comments

<<Previous

Investor Relations Q&A Updates for PTIE, ONCY, RIGL, INSV, SNTI

Weekend Biotech Reading List

"Fall is Here" Biotech Reading List

Bonus Mid-week Biotech Reading List

Investor Relations Q&A Updates for VICL, BTX, IGXT, PSDV, ENZ

Categories

Archives